It is now over a decade since the meningococcal B vaccine, MeNZB, was in routine use in New Zealand. From July 2004 until June 2008 it was administered in a three-dose schedule to over a million individuals, aged six weeks to 20 years, to provide protection against the epidemic strain of group B Meningococci. The cost of the campaign, including the development of the vaccine was substantial, in excess of $200M, but it contributed to a reduced incidence of meningococcal infections along with a reduction in morbidity and mortality. The campaign led to the development of a national immunisation register (NIR), which is still in existence today. As well as considering the legacies of the MeNZB vaccination programme, this paper examines whether there are any lessons to be learned, specifically concerning active vaccine safety monitoring, which may be important if, and when, a COVID-19 vaccine is developed and a national immunisation campaign instituted.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Decoding Alzheimer's Disease With Depression: Molecular Insights and Therapeutic Target.
J Cell Mol Med
March 2025
Department of Rehabilitation Medicine, The Third Hospital of Hebei Medical University, Shijiazhuang, P. R. China.
The purpose of this study was to recognise predictive biomarkers and explore the promising therapeutic targets of AD with depression. We confirmed a positive correlation between AD and depression through MR Analysis. Through WGCNA analysis, we identified 1569 genes containing two modules, which were most related to AD.
View Article and Find Full Text PDFEffectiveness of COVID-19 vaccines against laboratory-confirmed SARS-CoV-2 infection amongst health workers, Windhoek, Namibia.
Vaccine
March 2025
Robert Koch Institute, Am Nordufer 20, 13353 Berlin, Germany. Electronic address:
Introduction: As of 24 October 2021, 128,868 laboratory-confirmed COVID-19 cases and 3550 deaths were reported from Namibia. The national COVID-19 vaccination campaign that started in March 2021 included health workers (HWs) as a priority group. The vaccines most administered were Sinopharm, AstraZeneca, Pfizer-BioNtech, and Janssen.
View Article and Find Full Text PDFAn Overview of Predictive Biomarkers and Detection Approaches for Immunotherapy Response in GI Malignancies.
J Gastroenterol Hepatol
March 2025
Department of Radiology, Yunnan Cancer Center, Yunnan Cancer Hospital, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
This review provides an in-depth exploration of the evolving role of immunotherapy in gastrointestinal (GI) cancers, with a particular focus on immune checkpoint inhibitors (ICIs) and their associated predictive biomarkers. We present a detailed analysis of established biomarkers, such as PD-L1, microsatellite instability (MSI), tumor mutational burden (TMB), and the tumor microenvironment (TME), as well as emerging biomarkers, including gut microbiota and Epstein-Barr virus (EBV). The predictive value of these biomarkers in guiding clinical decision-making and optimizing immunotherapy outcomes is thoroughly discussed.
View Article and Find Full Text PDFSpatial prediction of immunity gaps during a pandemic to inform decision making: A geostatistical case study of COVID-19 in Dominican Republic.
Trop Med Int Health
March 2025
UQ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia.
Background: To demonstrate the application and utility of geostatistical modelling to provide comprehensive high-resolution understanding of the population's protective immunity during a pandemic and identify pockets with sub-optimal protection.
Methods: Using data from a national cross-sectional household survey of 6620 individuals in the Dominican Republic (DR) from June to October 2021, we developed and applied geostatistical regression models to estimate and predict Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike (anti-S) antibodies (Ab) seroprevalence at high resolution (1 km) across heterogeneous areas.
Results: Spatial patterns in population immunity to SARS-CoV-2 varied across the DR.
Identification and functional regulation of two alternative splicing isoforms of the Uhrf2 gene in Miichthys miiuy.
Dev Comp Immunol
March 2025
Laboratory of Fish Molecular Immunology, College of Fisheries and Life Science, Shanghai Ocean University, Shanghai, China; National Pathogen Collection Center for Aquatic Animals, Shanghai Ocean University, China; Key Laboratory of Freshwater Aquatic Genetic Resources, Ministry of Agriculture and Rural Affairs, Shanghai Ocean University, China. Electronic address:
Alternative splicing can produce a variety of splicing isoforms to increase protein diversity, participate in the regulation of gene expression and the occurrence and development of diseases, and thus play an important role in innate immunity. Ubiquitin like with PHD and ring finger domains 2 (Uhrf2) protein is associated with cell proliferation, inflammation, tumors and cancer, and is currently the focus of medical immunology research, but there is little research on alternative splicing of the Uhrf2 gene. In this study, we identified two different splice isoforms of Uhrf2 in Miichthys miiuy through Sanger sequencing, dual-luciferase reporter gene assay, qRT-PCR, subcellular localization experiments, and named them Uhrf2-α and Uhrf2-β.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!